We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Thermo Fisher Scientific - Direct Effect Media

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Research Center Tackles Antimicrobial Drugs Challenge

By HospiMedica International staff writers
Posted on 28 Mar 2017
Print article
Image: The new Liverpool Life Sciences Accelerator will help develop new antibiotics (Photo courtesy of LSTM).
Image: The new Liverpool Life Sciences Accelerator will help develop new antibiotics (Photo courtesy of LSTM).
A new state-of-the-art research center aims to accelerate the development of new antibiotics by providing researchers and commercial companies with access to pharmacodynamics research expertise, facilities, and training.

Established by the University of Liverpool, the Liverpool School of Tropical Medicine, and North Bristol NHS Trust, the Centre for Antimicrobial Pharmacodynamics (CAP) will be aligned with antimicrobial resistance (AMR) accelerators in the United States and Europe, and will provide a local resource for around 20 UK and 90 global AMR companies.

CAP will provide a complete, integrated drug development package, including experimental models for invasive bacterial and fungal diseases, comprised of laboratory animal models, hollow fiber models of infection, and other well characterized in vitro models of infection; advanced pharmacokinetics and pharmacodynamics (PK-PD) mathematical modeling, including population pharmacokinetics, drug interaction modeling, antimicrobial resistance modeling, and Monte Carlo simulation; and bioanalysis run to GCP standards for laboratories.

Other services provided will include preclinical imaging to assess the distribution of small molecules in target tissues and organs; underpinning PK-PD studies in early phase clinical studies in Liverpool or in other clinical research facilities; training future generations of researchers; and running bespoke short courses, plus participation in expert workshops. The CAP is also the first project to be announced as part of the newly launched Centre of Excellence in Infectious Diseases Research (CEIDR), a joint collaboration between the University of Liverpool and LSTM.

“Characterizing the preclinical and clinical pharmacokinetics and pharmacodynamics of anti-infective drugs is a relatively recent and mandatory regulatory requirement, which has created a bottleneck for AMR project progression because there is a lack of global skills and capacity to meet demand,” said Professor William Hope, MD, PhD, who will lead CAP. “The CAP will build on Liverpool’s existing strength in antimicrobial pharmacodynamics and therapeutics research to give scientists access to the skills and equipment they need to advance the development of new antibiotics.”

The new CAP facility will receive infrastructure funding from Innovate UK, an executive non-departmental public body of the UK government. In addition to the Innovate UK funding, the University of Liverpool will invest in new senior academic posts, while LSTM will contribute state-of-the-art laboratory space in the Liverpool Life Sciences Accelerator building, which is due to open in late 2017.


Print article

Channels

Critical Care

view channel
Image: EsoGuard has demonstrated over 90% specificity and 90% sensitivity in identifying Barrett’s Esophagus (Photo courtesy of Lucid Diagnostics)

Biomarker Based Non-Endoscopic Technology Identifies Risk for Esophageal Cancer

Barrett's esophagus (BE) is the benign and treatable precursor condition to esophageal adenocarcinomas (EAC) which is usually diagnosed at an advanced stage and is difficult to treat. Finding BE, a sign... Read more

Surgical Techniques

view channel
Image: Bio-glue enables near-instantaneous gelling, sealing and healing of injured tissue (Photo courtesy of Pexels)

Game-Changing ‘Bio-Glue’ Could End Use of Surgical Sutures and Staple

Tissue adhesive washout and detachment are major issues for medical practitioners and may prove fatal for patients, especially when the separation happens in vital organs like the lungs, liver and the heart.... Read more

Patient Care

view channel
Image: Future wearable health tech could measure gases released from skin (Photo courtesy of Pexels)

Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases

Most research on measuring human biomarkers, which are measures of a body’s health, rely on electrical signals to sense the chemicals excreted in sweat. But sensors that rely on perspiration often require... Read more

Health IT

view channel
Image: AI can reveal a patient`s heart health (Photo courtesy of Mayo Clinic)

AI Trained for Specific Vocal Biomarkers Could Accurately Predict Coronary Artery Disease

Earlier studies have examined the use of voice analysis for identifying voice markers associated with coronary artery disease (CAD) and heart failure. Other research groups have explored the use of similar... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.